# Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis

> **NCT00369239** · PHASE4 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 303 (actual)

## Conditions studied

- Schizophrenia
- Psychotic Disorders
- Schizoaffective Disorder

## Interventions

- **DRUG:** risperidone long acting injectable

## Key facts

- **NCT ID:** NCT00369239
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369239, "Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00369239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*